Company / Current Liabilities
Corvus Pharmaceuticals, Inc. Current Liabilities History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$35.4M
FY2024
5-year range
$6.9M / $35.4M
FY2020-FY2024
Trend
+415.4%
vs FY2023
Sector context
#171 of 215
Health Care
What the data says
Current Liabilities changed +415% YoY in FY2024, a notable deviation from the 9-year average annual change of +62%.
Based on SEC 10-K filings.
$35M in FY2024 with a 5-year CAGR of +28.2%.
Increased from $11M to $35M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +54.0%
- 5-Year CAGR
- +28.2%
- 10-Year CAGR
- -
Sector benchmark
Top 20% in Health CareTop 20% of 215This company $35.4M Sector average $1.6B
▼
-97.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +28.2%, indicating consistent growth.
- In FY2024, current liabilities increased 415.4% year-over-year.
- Ranks #171 out of 215 companies in the Health Care sector.
- Lowest current liabilities in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $35.4M | +415.4% |
| FY2023 | $6.9M | -36.1% |
| FY2022 | $10.8M | +10.9% |
| FY2021 | $9.7M | -20.2% |
| FY2020 | $12.1M | +18.8% |
| FY2019 | $10.2M | +45.5% |
| FY2018 | $7.0M | -21.7% |
| FY2017 | $9.0M | +50.9% |
| FY2016 | $5.9M | +93.6% |
| FY2015 | $3.1M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026